MOSCOW, 7 Jun — RIA Novosti. Drug “Levelmap”, created to treat complications COVID-19, originally wanted to use in rheumatoid arthritis, was told by the CEO of the Russian biotechnology company BIOCAD Dmitry Morozov.
“So how in the world has experience with this type of drugs for the treatment of patients with COVID-19, we have perepozitsionirovanie back and began clinical trials”, — quotes its words of RT.
In the pack are two syringes that doctors can put either simultaneously or with a slight delay. Then the patient only ten days under observation and then discharged.
Morozov said that it is completely original drug molecules which was created by the company. At first it was supposed to enter after the beginning of the patient’s cytokine storm, but the doctors of the Central clinical hospital of the presidential Administration, the clinical trials have developed their own mode of application.
“as soon As they see that a person has mild shortness of breath or other signs of disease COVID-19, which could result in aggravating the condition, they did begin to apply in advance”, — said Morozov.
Earlier in press service Biocad announced that the drug will go to the Russian hospital in about three weeks.
In Russia, the number of infected coronavirus infection exceeded $ 467 thousand people, the victims were 5689 patients.
